Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles (EVs) & Nanoparticles 2024: Diagnostics, Delivery, Therapeutics

Dominique PV de Kleijn's Biography



Dominique PV de Kleijn, Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands

Prof. Dr. Dominique PV de Kleijn is molecular biologist and chemist and professor of Exp. Vascular Surgery at UMC Utrecht and professor at the Netherlands Heart Institute. From 2012 to 2016, he was Research Professor of Surgery at NUS/NUHS and preclinical director of the Cardiovascular Research Institute (CVRI) Singapore. He was until 2016 professor of Cardiovascular Immunology and co-chair of Experimental Cardiology at UMC Utrecht. Since 1997 he is coordinating cardiovascular research from basic science, animal myocardial infarction and atherosclerotic studies (pig and sheep) towards clinical biobanking studies. His research interests are: The innate immune system in cardiovascular disease and atherosclerosis & Biomarkers predictive for primary & secondary events with a focus on plasma extracellular vesicles. He has more then 275 publications and a H-factor of 78.

Dominique PV de Kleijn Image

Plasma Extracellular Vesicles for Cardiovascular Disease

Wednesday, 3 April 2024 at 09:30

Add to Calendar ▼2024-04-03 09:30:002024-04-03 10:30:00Europe/LondonPlasma Extracellular Vesicles for Cardiovascular DiseaseExtracellular Vesicles (EVs) and Nanoparticles 2024: Diagnostics, Delivery, Therapeutics in Miami, FloridaMiami, FloridaSELECTBIOenquiries@selectbiosciences.com

Cardiovascular Disease (CVD) is with the cardiovascular events of Ischemic Heart Disease and Stroke, the number 1 and 2 cause of death in the world and expect to increase especially in Asia. Ischemic heart disease (IHD) comprises 2 entities: Chronic Coronary Syndrome (CCS) and Acute Coronary Syndrome (ACS). Because CCS is associated with 6-8 times increased risk of adverse cardiovascular events like myocardial infarction and death, early recognition of CCS. Blood markers for CCS do not exist, resulting in that 80-90% of chest pain patients undergoing costly imaging do not have CCS. We use plasma extracellular vesicle protein content of vesicles from plasma subfractions as an accurate source for early diagnosis of CCS better than a clinical risk model. Using automated plasma EV fraction analysis and CD9 as an internal marker, we hope with the plasma EV test to reduce the numbers of patients without CCS that are referred for costly imaging.


Add to Calendar ▼2024-04-03 00:00:002024-04-04 00:00:00Europe/LondonExtracellular Vesicles (EVs) and Nanoparticles 2024: Diagnostics, Delivery, TherapeuticsExtracellular Vesicles (EVs) and Nanoparticles 2024: Diagnostics, Delivery, Therapeutics in Miami, FloridaMiami, FloridaSELECTBIOenquiries@selectbiosciences.com